Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - AVADEL PHARMACEUTICALS PLC | ex10_1-form8k12012017.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 8, 2017
___________________
AVADEL PHARMACEUTICALS PLC
(Exact name of registrant as specified in its charter)
___________________
|
Ireland
(State or Other Jurisdiction of Incorporation) |
001-37977
(Commission File Number) |
98-1341933
(I.R.S. Employer
Identification No.) |
||||
|
Block 10-1
Blanchardstown Corporate Park, Ballycoolin Dublin 15, Ireland
(Address of Principal Executive Offices) |
Not Applicable
(Zip Code)
|
|||||
Registrant's telephone number, including area code: +353 1 485 1200
___________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company Ž
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Ž
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously announced on June 30, 2017, Avadel Pharmaceuticals plc (the "Company") received shareholder approval for its 2017 Omnibus Incentive Compensation Plan (the "2017 Omnibus Plan"), the complete text of which was set forth as Annex A to the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on May 1, 2017. In connection with the 2017 Omnibus Plan, the Company has adopted the U.S. Restricted Stock Unit Award Grant Notice and Agreement for restricted stock units to be issued from time to time under the 2017 Omnibus Plan, in the form attached hereto as Exhibit 10.1 which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
10.1
|
Form of U.S. Restricted Stock Unit Award Grant Notice and Agreement
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AVADEL PHARMACEUTICALS PLC
|
|||
|
By:
|
/s/ Phillandas T. Thompson
|
||
|
Phillandas T. Thompson
|
|||
|
Senior Vice President, General Counsel and Corporate Secretary
|
|||
Date: December 8, 2017
3
Exhibit Index
|
10.1
|
4